IIVS | New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-Cigarettes
1854
post-template-default,single,single-post,postid-1854,single-format-standard,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-4.11.2.1,vc_responsive

New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-Cigarettes

April 12, 2018
PMI Science

IIVS, in collaboration with Philip Morris International, recently presented data highlighting the predictive capability of in vitro assays in determining human response to non-burn tobacco products. Moreover, a ring trial of 6 independent laboratories has generated evidence that key events involved in human disease caused by nicotine-based products can be replicated using non-animal models. These results may increase interest in the use of alternative testing strategies for research and development and, eventually, regulatory acceptance.  Read article.